SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMEN
obligations may continue. See Instruction 1(b).	Filed p

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol TherapeuticsMD, Inc. [TXMD]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
MUSING JULES A.					<u>inci</u>	<u>up</u>	<u>cuticonii</u> ,	, <u> 1110</u>	<u>a</u> [17					X	Director			10% Ow	ner	
				— L										Officer (g	ive title		Other (s below)	pecify		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)								below)			below)			
951 YAMATO ROAD					08/10/2021															
SUITE 220																				
4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line)										
(Street) BOCA RATON FL 33431								X	X Form filed by One Reporting Person											
			55451												Form file	d by More	e than C	One Reporti	ng Person	
(City)		State)	(Zip)																	
			Table I - Non	-Deriva	ative	Sec	curities Ac	quir	ed, D	isp	osed o	of, or E	ene	ficially C	wned					
Date					th/Day/Year) if any		Execution Date,		Code (Instr.				(A) or 3, 4 and 5)	5. Amount Securities Beneficially Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								C	ode \	,	Amount	(A) or (D) P		Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 08/1				08/10/	10/2021			М		96,864 A		(1)	101,8	101,864		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)	action D (Instr. S A D		Number of rivative curities quired (A) or sposed of (D) str. 3, 4 and	6. Date Exercisa Expiration Date (Month/Day/Yea				7. Title and Amou Securities Under Derivative Securi (Instr. 3 and 4)		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number derivativ Securitie Beneficia Owned Followin Reported Transact	ve (es l ally l ig (d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exerc	cisable		xpiration ate	Title	N	mount or umber of nares		(Instr. 4)				
Restricted Stock Units	\$0	08/10/2021		М			96,864 ⁽¹⁾⁽²⁾	(3)		(3)		Commo Stock		6 ,86 4 ⁽¹⁾⁽²⁾	64 ⁽¹⁾⁽²⁾ \$0			D		

Explanation of Responses:

1. On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

2. Each RSU represented a contingent right to receive one share of issuer common stock upon settlement.

3. The RSUs vested on June 18, 2021.

/s/ Jules A. Musing

** Signature of Reporting Person

<u>08/12/2021</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.